![]() The lab has the capacity to process thousands of genomic tests per day - vital to Sema4’s efforts to provide information related to thousands of genetically identifiable diseases to patients across the country. Last December, it announced the opening of an approximately 70,000-square-foot lab in Stamford’s Waterside section. ![]() Since its 2017 spinoff from the Mount Sinai Health System into its own firm, Sema4 has expanded significantly in Connecticut. Last year, the company received a $121 million infusion from a group of backers that included the state-chartered investment agency Connecticut Innovations and Greenwich-based venture capital firm Oak HC/FT. From 2014 to 2015, she led a 300-person global sales, consulting services, and marketing team as the Chief Revenue Officer of publicly-traded Rally Software. Sema4 had already attracted major investments. David Michel, D-Stamford and other elected officials during a tour of Sema4's lab at 62 Southfield Ave., in Stamford, Conn., on Sept. Sema4 founder and CEO Eric Schadt of Sema4, center, talks with Sen. “It helps capture the value of the market today, helps set the (stock) price and gives you security.” “It’s sort of an IPO in reverse because you’re setting the price up front, doing the ‘road show’ up front with getting all these big-name public investors signed up and then you do that ‘merger’ agreement and get ready to be public,” Sema4 founder and CEO Eric Schadt said in February, when the company’s plan to go public was announced. In a major sign of confidence in the company’s prospects, institutional investors are contributing a total of $350 million of “private investment in public equity.”
0 Comments
Leave a Reply. |